X4 Pharmaceuticals, Inc

Biological Products, (No Diagnostic Substances)

XFOR Pharmaceuticals & Biotechnology People in Pharmaceuticals & Biotechnology SEC CIK 0001501697 ↗

Computed from SEC EDGAR filings and closing prices — not copied from any wealth ranking. Dataset . How we calculate this.

Market capitalisation
$347.01M
99,146,743 shares Covers every share class this company has on file.
Insiders on file
9
people who have filed Form 3, 4 or 5 naming this issuer
Value of insider-held stock
$29.32M
from the holdings reported on Forms 3/4/5; this figure has no separate as-of date on file
Insider-held share of market cap
8.45%
insider-held value divided by market capitalisation

What X4 Pharmaceuticals, Inc reports

Revenue and net income below are for fiscal period FY2025, the period label carried by this company’s own annual XBRL filings to the SEC. Fiscal years do not line up between companies — one company’s FY2026 can cover much the same months as another’s FY2025 — so compare the periods, not just the numbers.

Revenue
$6.50M
FY2025 annual revenue, from this company’s own annual XBRL filings to the SEC
Net income
-$79.20M
FY2025 a loss for the period, from this company’s own annual XBRL filings to the SEC
Employees
45
Yahoo Finance
Where the employee count comes from

Headcount comes from Yahoo Finance, not from a filing. The date beside it is the day we retrieved the figure — it is not the date the company counted its staff, and Yahoo does not publish that date. Unlike the SEC filings behind the other figures on this page, this one carries no open licence, so we publish the number and nothing else from that source.

Insiders at X4 Pharmaceuticals, Inc

Shares is what each person last reported holding here.

Everyone below has filed at least one insider report against this company.

Value is that share count priced at the same closing price used everywhere else on this site. A row priced from only some of a person’s securities says so — we do not quietly present a partial sum as a complete one.

Rows are grouped by the role each person reports.

The role comes from the relationship boxes a person ticks on their own insider filings — officer, director, ten per cent owner — not from anything we infer. Somebody who is both an officer and a director appears once, in the combined group, so the row count still matches the figure at the top of this page. Where no filing states a role we say so instead of guessing one.

People who file insider reports against X4 Pharmaceuticals, Inc.
Insider Reported role Shares Value Last action
Officers 5
Mary DiBiase COO 1,140,980 $4.61M A Grant or award Feb 12, 2025 position reported
Christophe Arbet-Engels Other Executive 864,207 $3.49M A Grant or award Feb 12, 2025 position reported
Adam S Mostafa CFO 850,000 $3.43M A Grant or award Feb 12, 2025 position reported
Arthur Taveras Other Executive 388,026 $1.57M S Open-market sale Oct 7, 2024 position reported
John Volpone President 289,881 $1.17M S Open-market sale Aug 12, 2026 position reported
Officers who also sit on the board 3
Paula Ragan CEO 3,337,386 $13.48M A Grant or award Feb 12, 2025 position reported
Adam R Craig Executive Chairman 376,087 $1.52M S Open-market sale Aug 12, 2026 position reported
Keith Woods COO 6,000 $24.2K A Grant or award Jun 9, 2025 position reported
Directors 1
David W. J. McGirr Board Member 4,722 $19.1K A Grant or award Jun 9, 2025 position reported

Recent insider transactions

Of the 32 rows we hold, 1 are open-market purchases (P) and 13 open-market sales (S) — the only codes we count as buying or selling.

The rest — awards, shares withheld to pay tax, option exercises, gifts and so on — follow from an employment contract or a transfer arranged off-market, not from a decision to buy or sell, so counting them would turn this into a pay table.

A price of 0.00 is a real reported figure on gifts (G) and share awards (A) — not a gap in our data.

Insider transactions disclosed to the SEC for X4 Pharmaceuticals, Inc, newest first, each with the filing behind it.
Date Insider Transaction Shares Price Value Filing
Aug 12, 2026 John Volpone S Open-market sale 24,576 $4.44 $109.1K SEC filing ↗
Aug 12, 2026 Adam R Craig S Open-market sale 47,436 $4.44 $210.6K SEC filing ↗
Oct 23, 2025 Adam R Craig P Open-market purchase 86,206 $2.90 $250.0K SEC filing ↗
Aug 14, 2025 John Volpone A Grant or award 289,881 $0.00 $0 SEC filing ↗
Aug 14, 2025 Adam R Craig A Grant or award 289,881 $0.00 $0 SEC filing ↗
Jun 9, 2025 Keith Woods A Grant or award 1,500 $0.00 $0 SEC filing ↗
Jun 9, 2025 David W. J. McGirr A Grant or award 1,500 $0.00 $0 SEC filing ↗
Feb 12, 2025 Mary DiBiase A Grant or award 650,000 $0.00 $0 SEC filing ↗
Feb 12, 2025 Christophe Arbet-Engels A Grant or award 850,000 $0.00 $0 SEC filing ↗
Feb 12, 2025 Paula Ragan A Grant or award 2,250,000 $0.00 $0 SEC filing ↗
Feb 12, 2025 Adam S Mostafa A Grant or award 850,000 $0.00 $0 SEC filing ↗
Jan 24, 2025 Mary DiBiase S Open-market sale 22,258 $0.45 $10.0K SEC filing ↗
Jan 24, 2025 Christophe Arbet-Engels S Open-market sale 11,624 $0.45 $5.2K SEC filing ↗
Jan 24, 2025 Paula Ragan S Open-market sale 76,473 $0.45 $34.4K SEC filing ↗
Jan 24, 2025 Adam S Mostafa S Open-market sale 74,773 $0.45 $33.6K SEC filing ↗
Jan 23, 2025 Mary DiBiase A Grant or award 61,178 $0.00 $0 SEC filing ↗
Jan 23, 2025 Christophe Arbet-Engels A Grant or award 25,831 $0.00 $0 SEC filing ↗
Jan 23, 2025 Paula Ragan A Grant or award 169,940 $0.00 $0 SEC filing ↗
Jan 23, 2025 Adam S Mostafa A Grant or award 74,773 $0.00 $0 SEC filing ↗
Nov 15, 2024 Paula Ragan S Open-market sale 31,897 $0.39 $12.4K SEC filing ↗
Oct 15, 2024 Paula Ragan S Open-market sale 31,897 $0.56 $17.9K SEC filing ↗
Oct 7, 2024 Arthur Taveras S Open-market sale 76,920 $0.56 $43.1K SEC filing ↗
Oct 7, 2024 Mary DiBiase S Open-market sale 67,695 $0.57 $38.6K SEC filing ↗
Oct 7, 2024 Paula Ragan S Open-market sale 239,436 $0.55 $131.7K SEC filing ↗
Oct 7, 2024 Adam S Mostafa S Open-market sale 230,645 $0.55 $126.9K SEC filing ↗

From SEC Form 4 filings. Every row links to the filing it came from. How we calculate this.

What a Form 4 is

The report an officer, director or large shareholder must file after trading their own company’s stock.

Think a number here is wrong? Open the linked filing and compare — how to report it.

Sources and technical notes

Every figure on this page comes from filings to the U.S. SEC via EDGAR. Nothing here is estimated, and nothing is taken from press coverage or company websites.

Share count: cover page of the latest filing (dei:EntityCommonStockSharesOutstanding), taken from X4 Pharmaceuticals, Inc’s own filings and multiplied by our closing price. Full method.

What that share count means

the share count the company itself prints on the cover of its most recent filing, as of the date it signed that filing.

We do not take a market cap from a data vendor, and we do not estimate one: the figure is a share count from X4 Pharmaceuticals, Inc’s own SEC filings multiplied by the closing price we hold for the same stock.